Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

NCT06929299 is registered in ClinicalTrials.gov with Jiangsu BioJeTay Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06929299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06929299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
Lead sponsor
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 12, 2025
Completion date
September 30, 2026
Enrollment
56 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune thrombocytopenia (itp)